摘要
背景 近几年，随着对免疫系统参与MM研究的不断深入，单克隆抗体逐渐成为MM治疗性用药的研究热点。目的 分析CD38单克隆抗体－达雷妥尤单抗治疗多发性骨髓瘤的疗效及安全性，探讨其在临床应用中的进展及优势，为其临床用药提供依据。方法 回顾性分析新疆维吾尔自治区人民医院血液科2016年8月—2022年3月期间住院并接受达雷妥尤单抗治疗的10例多发性骨髓瘤患者临床资料,随访分析疗效及不良反应。结果 10例多发性骨髓瘤患者中8例可进行疗效评估,总体缓解率（ORR）为62.5%，其中6/10患者出现淋巴细胞减少，4/10患者出现了血小板减少和中性粒细胞减少，应用达雷妥尤单抗治疗后血清游离轻链水平均明显下降。结论 达雷妥尤单抗在治疗多发性骨髓瘤中具有较好的临床疗效和安全性，且在清除血清游离轻链中发挥了一定的作用，其应用前景值得期待。
关键词： 达雷妥尤单抗；多发性骨髓瘤；疗效；进展
Abstract
Background: In recent years, with the continuous deepening of the immune system's participation in MM research, monoclonal antibodies have gradually become a research hot spot for MM therapeutic drugs. Objective：To analyze the efficacy and safety of CD38 monoclonal antibody-marriageability in the treatment of multiple myeloma, to explore its progress and advantages in clinical application, and to provide a basis for its clinical use. Methods: The clinical data of 10 patients with multiple myeloma who were hospitalized and treated with marriageability from August 2016 to March 2022 in the Department of Hematology of Xinjiang Augury Autonomous Region People's Hospital were retrospectively analyzed, and the efficacy and adverse reactions were followed up to analyze the efficacy and adverse reactions. Results Eight of the 10 patients with multiple myeloma could be evaluated for efficacy, and the overall response rate (ORR) was 62.5%, of which 6/10 patients had lymphopenia, 4/10 patients had thrombocytopenia and neutropenia, and the serum free light chain level decreased significantly after treatment with marriageability. Conclusion : marriageability has good clinical efficacy and safety in the treatment of multiple myeloma, and plays a certain role in clearing the free light chain of serum, and its application prospects are worth looking forward to.
Key words： Daratumumab; Multiple Myeloma; Efficacy; Progress
参考文献 References
[1] Cowan Andrew J, Green Damian J, Kwok Mary et al. Diagnosis and Management of Multiple Myeloma: A Review.[J] .JAMA, 2022, 327: 464-477.
[2] Vozella Federico, Siniscalchi A, Rizzo M et al. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.[J] .Ann Hematol, 2021, 100: 1059-1063.
[3] Durie BG, Salmon SE. A clinical staging system for multiplemyeloma. Correlation of measured myeloma cell mass withpresenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3):842‑854.
[4] Palumbo A, Avet‑Loiseau H, Oliva S, et al. Revisedinternational staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015, 33(26):2863‑2869.
DOI: 10.1200/JCO.2015.61.2267.
[5] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订)[J]. 中华内科杂志 2020年59卷5期, 341-346页, MEDLINE ISTIC PKU CSCD CA, 2021.
[6] KUMAR S K，DISPENZIERI A，LACY M Q，et al. Continued improvement in survival in multiple myeloma：changes in early mortality and outcomes in older patients[J]. Leukemia, 2014, 28 (5): 1122-1128.
DOI：10.1038/leu.2013.313.
[7] Sunder-Plassmann Vincent, Aksoy Osman, Lind Judith et al. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: An early 2022 glance into the future.[J] .Expert Opin Pharmacother, 2022, undefined: undefined.
[8] Mateos M V, Dimopoulos M A, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma[J]. N Engl J Med, 2018, 378(6):518-528. DOI: 10.1056/NEJMoa1714678.
[9] Perrot Aurore, Facon Thierry, Plesner Torben et al. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.[J] .J Clin Oncol, 2021, 39: 227-237.
[10] Moreau Philippe, Hulin Cyrille, Perrot Aurore et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.[J] .Lancet Oncol, 2021, 22: 1378-1390.